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Low molecular weight peptidomimetic inhibitors with hydrophobic pocket binding properties 
and moderate fusion inhibitory activity against HIV-1 gp41-mediated cell fusion were elaborated 
by increasing the available surface area for interacting with the heptad repeat-1 (HR1) coiled coil 
on gp41.  Two types of modifications were tested: 1) increasing the overall hydrophobicity of the 
molecules with an extension that could interact in the HR1 groove, and 2) forming symmetrical 
dimers with two peptidomimetic motifs that could potentially interact simultaneously in two 
hydrophobic pockets on the HR1 trimer.  The latter approach was more successful, yielding 40 – 
60 times improved potency against HIV fusion over the monomers.  Biophysical 
characterization, including equilibrium binding studies by fluorescence and kinetic analysis by 
Surface Plasmon Resonance, revealed that inhibitor potency was better correlated to off-rates 
than to binding affinity. Binding and kinetic data could be fit to a model of bidentate interaction 
of dimers with the HR1 trimer as an explanation for the slow off-rate, albeit with minimal 
cooperativity due to the highly flexible ligand structures. The strong cooperativity observed in 
fusion inhibitory activity of the dimers implied accentuated potency due to the transient nature of 
the targeted intermediate.  Optimization of monomer, dimer or higher order structures has the 
potential to lead to highly potent non-peptide fusion inhibitors by targeting multiple hydrophobic 
pockets. 
 
Keywords: HIV-1 gp41; hydrophobic pocket; fusion inhibition; peptidomimetic inhibitors, 





The hydrophobic pocket (HP) on the surface of the gp41 trimeric HR1 coiled coil is an 
important target for antiretroviral drugs against HIV fusion.
1
 The pocket sits at the interface 
between HR1 and helical HR2 segments which wrap down the sides of the coiled coil to form a 
six-helix bundle structure upon successful virus – host membrane fusion (Figure 1A).
2, 3
 The 
pocket is exposed to inhibitors for 20 – 30 minutes during a conformational change of gp41 prior 
to six-helix bundle formation.
4
 Small molecules that bind in this pocket have been developed 
into low to sub-µM inhibitors of HIV entry,
5-8
 but so far efforts at small molecule discovery have 
failed to achieve the potency afforded by C-peptides derived from HR2.
9, 10
 These are nM 
inhibitors, including T20 which is an FDA-approved fusion inhibitor.
11
 Non-peptide inhibitors of 
HIV fusion could have advantageous properties as drugs, such as longer half-life and lower cost 
and the potential for oral bioavailability.  
One approach to improving potency of small molecules is to extend them to form 
additional interactions with HR1 beyond the hydrophobic pocket.  HR1 has multiple potential 
interactive sites both within a single groove and between adjacent grooves of the trimer.  
Bidentate ligands are generally 1 – 2 orders of magnitude more potent than their monomeric 
counterparts against targets with more than one binding site.
12, 13
 To our knowledge, this concept 
has not been tested with small molecule inhibitors targeting gp41.  For C-peptides, the effect of 
multivalent interactions is clear.  18 residue HP-binding C-peptides containing the motif 
WxxWDxxI are low µM binders
14, 15
 and fusion inhibitors,
16
, while 34 residue C-peptides have 
low nM activity.
17
 Dimerization  of 22 residue helical C-peptides improved activity by a factor of 
9.
18
 Similarly, D-peptides designed to bind in the hydrophobic pocket
19
 have activity improved 
  
4 
by 10 – 300 fold upon dimerization with a long polyethylene glycol (PEG) linker, presumably by 
simultaneous interactions in two HP’s of the trimer.
20, 21
  
An important consideration in designing extension or dimerization of small molecule 
hydrophobic pocket binders is selection of a tether that will not disturb the binding mode. Helical 
peptidomimetics are suitable candidates for this approach because they are designed to emulate 
the amphipathic C-peptide helix, which has HP binding residues on one face of the helix (Fig 
1B).  
 
Figure 1.  Experimental and model structures of the gp41 HR1 – HR2 domain 
and interactions.  A. Homology modeling of HIV-1 HXB2 ectodomain from 
the structure of the corresponding SIV domain (pdb 2EZO).  The HR1 trimer 
is shown as a space filling model in tan, and loop and HR2 residues are shown 
as a ribbon representation in yellow; B. Expansion of the hydrophobic pocket 
region from A.  C, D. Modeled low energy structures of two subunit and three 
subunit peptidomimetics with Trp and Leu residues filling the pocket.  See 
Figure 2 for the structures of the peptidomimetic inhibitors. 
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Peptidomimetic inhibitors are expected to have side chains occupying the pocket while the non-
peptidic “backbone” is exposed above the pocket and available for tethering.  
We previously examined a combinatorial library of three-subunit peptidomimetics 











-OH , developed by the Boger group.
22
 
Screening with a binding assay for the gp41 hydrophobic pocket revealed a clear propensity for 




, especially for Trp, Nap and Phe4Cl.
23
 Ile was also well-tolerated 
at R
1
 in three subunit compounds with an aryl R
3
, consistent with the inhibitors emulating the 
conserved WWI motif of gp41 C-peptides. The compounds H2N-Asn-[Trp]-Trp-COOH (KI = 0.8 
µM, IC50
CCF
 = 6 µM) and H2N-Trp-[Trp]-Leu-COOH (KI = 1.3 µM, IC50
CCF
 = 5 µM) were 
among the most potent compounds.  In the absence of R
3
 in the two subunit compounds, R
2
 = 
Trp or Nap and R
1
 = Trp, Nap or Phe4Cl were the optimal choices.  Bioactivity was reduced by a 
factor of ~4 compared to the three subunit compounds listed.
24
 
Most low energy simulated structures adopted the predicted binding pose in which the 
side chains reached down into the pocket and the aryl alkoxy “backbone” lay above the pocket 
(Figure 1C, D). NMR paramagnetic relaxation enhancement measurements on two inhibitors of 
this class, O2N-[HoPhe]-Ala-OH and O2N-[Ala]-Nap-OH confirmed this binding mode.
24
   We 
selected two subunit compounds with R
1
 = Trp or Phe4Cl and R
2
 = Trp to explore attachment of 
a tether to the aryl alkoxy moiety, and to evaluate the effect of extension or dimerization on 
binding affinity and inhibition of virus – cell and cell – cell fusion.  
 
2. Materials and Methods 
2.1 Synthetic chemistry 
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2.1.1. Sources  3-fluoro-4-nitrobenzoic acid was purchased from Matrix Scientific (Fisher), 3-(2-
hydroxyethyl)indole, Zn nanopowder, was purchased from Sigma-Aldrich.  THF was purchased 
from EMD Millipore (VWR).  4-chlorobenzylalcohol was purchased from Alfa Aesar.  L-
tryptophan tert-butyl ester hydrochloride was purchased from Chem-Impex International.   
2.1.2 Preparation of the aryl subunits The aryl subunits were synthesized following the 





 = 3-ethyleneindole.  Sodium hydride (60%, 0.5 g, 12.5 mmol) and 3-(2-
hydroxyethyl)indole (1.0 g, 5.4 mmol) were stirred in 10ml THF at 0°C for 15 minutes, after 
which 3-fluoro-4-nitrobenzoic acid (1.04 g, 6.45 mmol) was added.  The mixture was stirred at 
0°C overnight, and then quenched with aqueous saturated NH4Cl, diluted with ethyl acetate, 
washed with 0.1M HCl (50ml, x 2).  The organic layer was concentrated and purified by silica 
gel chromatography (10:1 DCM/ MeOH, 1% acetic acid) , affording 2.6 g pure product (74%). 
Data for 1: 
1
H NMR (DMSO)  7.87 (d, 1H, J = 8.4 Hz), 7.81 (s, 1H), 7.62 (dd, 1H, J = 8.3 Hz, 
0.8 Hz), 7.58 (d, 1H, J = 7.8 Hz), 7.36 (d, 1H, J = 8.0 Hz), 7.23 (d, 1H, J = 1.9 Hz), 7.07 (t, 1H, J 
= 7.3 Hz), 6.98 (t, 1H, J = 7.4 Hz), 4.43 (t, 2H, J = 6.9 Hz), 3.18 (t, 2H, J = 6.9 Hz). 
2. R2 = 4-chlorobenzyl.  Sodium hydride (60%, 0.68 g, 17 mmol) and 4-chlorobenzylalcohol 
(1.21 g, 8.5 mmol) were stirred in 15ml THF at 0°C for 15 minutes, after which 3-fluoro-4-
nitrobenzoic acid (1.5 g, 8.1 mmol) was added.  The mixture was stirred at 0°C overnight, and 
then quenched with aqueous saturated NH4Cl, diluted with ethyl acetate, washed with 0.1M HCl 
(75ml, x 2) and brine.  The organic layer was concentrated and separated by silica gel 
chromatography (3:2:0.1 hexanes/ ether/acetic acid  10 : 1 DCM/MeOH) to yield 2.2 g product 
5 (89%). Data for 2: 
1
H NMR (DMSO)  8.00 (d, 1H, J = 8.3 Hz), 7.86 (d, 1H, J = 1.4 Hz), 7.67 
(dd, 1H, J = 8.3 Hz, 1.5 Hz), 7.49 (s, 4H), 5.39 (s, 2H). 
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3a. (O-tBu) Compound 1 (605 mg, 1.85 mmol) and L-Trp t-butyl ester (550 mg, 1.85 mmol) 
were combined in 12ml dry DMF to which EDCI (426 mg, 2.22 mmol), HOBt (300mg, 2.22 
mmol) and DIPEA (0.97 ml, 5.57 mmol) were added.  The solution was stirred overnight, then 
diluted with EtOAc, washed with sodium bicarbonate, 10% NaCl (x2), brine, and then 
concentrated.  850 mg of product was obtained on a flash column in 40% EtOAc /hexane, Rf = 
0.35 and used immediately for the next reaction.   The product (850 mg, 1.49 mmol) was reduced 
by dissolving it in 24 ml of 5:1 acetone : water and adding Zn nanopowder (978 mg, 15.0 mmol), 
and NH4Cl (1.2 g, 22.4 mmol).  An instantaneous exothermic reaction occurred, after which the 
mixture was filtered, diluted with 1 : 1 EtOAc/ether, washed with bicarbonate and brine and 
evaporated. The solid was triturated and purified by silica gel chromatography (50% 
EtOAc/hexane) to afford 3 in quantitative yield.  Data for 3a: Rf =0.30 (50% EtOAc/hexane); 




H NMR (CDCl3)  8.16 (br, 1H), 8.05 (br, 1H), 7.65 (d, 
1H, J = 7.9 Hz), 7.60 (d, 1H, J = 7.9 Hz), 7.36 (d, 1H, J = 8.0 Hz), 7.25 (m, 1H), 7.20 (m, 2H), 
7.16 – 6.99 (m, 6H), 6.54 (d, 1H, J = 8.1 Hz), 6.50 (d, br, 1H, J = 7.52), 5.02 (m, 1H), 4.19 (t, 
2H, J = 6.7 Hz), 3.37 (m, 2H), 3.22 (t, 2H, J = 6.7 Hz), 1.40 (s, 9H).   
3. Ester 3a (213 mg, 0.396 mmol) was taken up in dry HCl in dioxane (4 M, 6.0 mL), stirred for 
1.5 h, and concentrated. Purification by silica gel chromatography (1:4 MeOH:DCM) and 
filtration through a plug of Celite using acetone as the solvent yielded carboxylic acid 3 (180 mg, 




H NMR (acetone)  7.68 (m, 
2H), 7.41 – 7.25 (m, 6H), 7.13 – 6.96 (m, 4H), 6.65 (d, 1H, J = 7.7 Hz), 5.00 (m, 1H), 4.19 (t, 
2H, J = 6.6 Hz), 3.47 – 3.35 (m, 2H), 3.24 (t, 2H, J = 6.6 Hz). 
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4a. (O-tBu) Compound 4 was prepared from compound 2 using the same method as for 
preparation of compound 3.  Purification by silica gel chromatography (40% EtOAc/hexane) 
yielded 4 (781 mg, 92%).  Data for 4: Rf = 0.18 (40% EtOAc/ hexane); 
1
H NMR (CDCl3)  9.14 
(br, 1H), 8.32 (d, 1H, J = 8.4 Hz), 7.94 (s, 1H), 7.58 (d, 1H, J = 7.9 Hz), 7.30 – 7.24 (m, 6H), 
7.13 – 7.07 (m, 2H), 7.02 (m, 2H), 6.92 (d, 1H, J = 7.4 Hz), 4.97 (q, 1H, J = 7.0 Hz), 4.81 (br, 
2H), 3.36 (m, 4H)  
4.  Ester 4a (168 mg, 0.324 mmol) was taken up in dry HCl in dioxane (4 M, 3.0 mL), stirred for 
1 h, and concentrated. Purification by silica gel chromatography (1:9 MeOH:DCM) yielded 





(acetone)  7.68 (d, 1H, J = 7.8 Hz), 7.48 – 7.36 (m, 6H), 7.30 – 7.28 (m, 2H), 7.08 (t, 1H, J = 
7.7 Hz), 7.01 (t, 1H, 7.4 Hz), 6.68 (d, 1H, J = 8.0 Hz), 5.04 (s, 2H), 5.00 (br, ~1H), 3.5-3.4 (m, 
2H). 
2.1.4 Preparation of bivalent compounds 
5.  Solution of amine 3a (543 mg, 1.01 mmol) and succinic anhydride (134 mg, 1.33 mmol) in 
THF (10 mL) was stirred for 4 h at 65°C. Purification by silica gel chromatography (7:3 
EtOAc/hexane) afforded 5 (637 mg, 99%).  Data for 5: Rf = 0.40 (10:1 DCM:MeOH). 
1
H NMR 
(CDCl3)  8.75 (s, 1H), 8.65 (s, 1H), 8.16 (d, 1H, J = 8.2 Hz), 7.72 (s, 1H), 7.57 (d, 1H, J = 7.9 
Hz), 7.53 (d, 1H, J = 7.3 Hz), 7.28 – 7.22 (m, 3H), 7.12 – 6.99 (m, 5H), 6.96 (d, 1H, J = 1.8 Hz), 
6.89 (d, 1H, J = 7.6 Hz), 6.84 (d, 1H, J = 1.7 Hz), 5.00 (q, 1H, J = 7.4 Hz, 5.8 Hz), 3.99 (t, 2H, J 
= 5.5 Hz), 3.44 – 3.29 (m, 2H), 3.02 (t, 2H, J = 5.5 Hz), 2.54 (t, 2H, J = 6.1 Hz), 2.20 (t, 2H, J = 
5.8 Hz), 1.42 (s, 9H). 
6. Solution of amine 4a (456 mg, 0.88 mmol) and succinic anhydride (111 mg, 1.10 mmol) in 
THF (8 mL) was stirred overnight at 54°C. Purification by silica gel chromatography (4:1 
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EtOAc/hexane  EtOAc) afforded 6 (306 mg, 56%).  Data for 6: 
1
H NMR (CDCl3)  8.86 (s, 
1H), 8.21 (d, 1H, J = 8.2 Hz), 8.08 (s, 1H), 7.57 (d, 1H, J = 7.7 Hz), 7.30 – 7.27 (m, 4H); 7.22 – 
7.20 (m, 2H), 7.11 – 7.07 (m, 2H), 7.04 – 7.00 (m, 2H), 6.95 (d, 1H, J = 7.6 Hz), 4.98 (q, 1H, J = 
7.3 Hz, 5.7 Hz), 4.82 (s, 2H), 3.42 – 3.29 (m, 2H), 2.69 – 2.58 (m, >4H), 1.41 (s, 9H). 
7  Solution of triethylene glycol diamine (H2N-(CH2CH2O)3–CH2CH2NH2) (24.6 mg, 0.128 
mmol), carboxylic acid 5 (130. mg, 0.204 mmol), EDCI.HCl (54.0 mg, 0.282 mmol), HOAt 
(37.2 mg, 0.273 mmol) and DIPEA (0.11 mL, 0.63 mmol) in DMF (2.0 mL) was stirred for 18 h. 
Purification by silica gel chromatography (10:1 DCM:MeOH) afforded the intermediate tBu 
ester-protected dimer (143 mg). Data for tBu ester-protected dimer: 
1
H NMR (CDCl3)  9.32 (s, 
br, 1H), 8.95 (s, br, 1H), 8.13 (d, 1H, J = 8.5 Hz), 7.99 (s, 1H), 7.86 (s, 1H), 7.55 (m, 2H), 7.32 
(d, 1H, J=7.9 Hz), 7.26 (d, 1H, J = 8.5 Hz), 7.22 (s, br, 1H), 7.08 (m, 3H), 7.00 (m, 2H), 6.95 (d, 
1H, J=1.9 Hz), 6.91 (d, 1H, J=7.5 Hz), 6.86 (t, 1H, J=5.1 Hz), 4.98 (q, 1H, J=7.0 Hz), 4.01 (t, 
2H, J=5.9 Hz), 3.52 (br, 4H), 3.46 (t, 2H, J=4.6 Hz), 3.38 (m, 4H), 3.06 (t, 2H, J=5.4 Hz), 2.36 
(m, 4H), 1.41 (s, 9H). 
This intermediate (143 mg) was taken up in dry HCl in dioxane (4 M, 2.0 mL), stirred for 70 
min, and concentrated under a stream of Ar. Purification by silica gel chromatography (10:1 
DCM:MeOH  4:1 [90:10:0.6:0.6 CH2Cl2:MeOH:H2O:NH4OH]:MeOH) afforded dimer 7 (55.4 
mg, 41% over 2 steps). Data for 7: Rf = 0.20 (10:1 DCM:MeOH); MS calculated: 1335.43 




H NMR (DMSO)  9.09 (s, 0.5H), 9.02 (s, 0.5H), 
8.73 (d, 0.6H, J = 7.5 Hz), 8.11 (d, 1H, J=8.2 Hz), 8.05 (m, 2H), 7.64 (m, 1H), 7.55 (t, 1H, J=7.5 
Hz), 7.45 (m, 2H), 7.33 (m, 4H), 7.25 (d, 1H, J = 8.1 Hz), 7.18 (d, 1H, J =2.0 Hz), 7.11 – 6.82 




8. Solution of triethylene glycol diamine (H2N-(CH2CH2O)3–CH2CH2NH2) (47.4 mg, 0.246 
mmol), carboxylic acid 6 (306 mg, 0.493 mmol), EDCI.HCl (117 mg, 0.610 mmol), HOAt (81.4 
mg, 0.598 mmol) and DIPEA (0.26 mL, 1.49 mmol) in DMF (4.0 mL) was stirred for 18 h and 
then concentrated. Purification by silica gel chromatography (10:1 DCM:MeOH) afforded the 
intermediate tBu ester-protected dimer (107 mg) along with 6 (159 mg).  Data for tBu-ester-
protected dimer: 
1
H NMR (CDCl3)  8.91 (s, br, 1H), 7.58 (d, 1H, J=7.8 Hz), 7.31 (s, 1H), 7.25 
(m, 5H), 7.16 – 7.03 (m, 6H), 6.94 (d, 1H, J=2.1 Hz), 6.85 (d, 1H, J=7.5 Hz), 4.99 (1H), 4.98 (s, 
2H), 3.59 (m, 4H), 3.51 (m, 2H), 3.41 (m, 4H), 2.64 (m, 4H), 1.41 (s, 9H). 
This intermediate (107 mg) was taken up in dry HCl in dioxane (4 M, 1.5 mL), stirred for 65 
min, and concentrated under a stream of Ar. Purification by silica gel chromatography 
(90:10:0.6:0.6 CH2Cl2:MeOH:H2O:NH4OH  9:1 [90:10:0.6:0.6 CH2Cl2:MeOH:H2O:NH4OH]: 





H NMR (DMSO)  9.40 (s, br, 0.3H), 9.29 (s, br. 0.6H), 7.98 (m, 
2H), 7.57 (dd, 2H, J=6.9, 2.1 Hz), 7.52 (d, 1H, J=6.9 Hz), 7.45 (dm 2H, J=8.6 Hz), 7.40 (s, 1H), 
7.35 (d, 1H, J=8.1 Hz), 7.27 (d, 1H, J=8.1 Hz), 7.22 (m, 1H), 7.07 (m, 1H), 6.99 (t, 1H, J=7.7 
Hz), 6.85 (t, 1H, J=7.2 Hz), 4.89 (1H, d, J=5.0 Hz), 4.68 (m, 2H), 4.13 (q, 4H, J=5.1 Hz), 2,66 
(m, 2H), 2.35 (m, 4H).  (Note: A residual water peak at 3.33 ppm masks peaks in that region) 
2.1.5 Preparation of extended monomers 
9. To a solution of indole-3-propionic acid (0.62 g, 3.3 mmol) and 6-aminohexanoic acid methyl 
ester* (0.60 g, 3.3 mmol) in 20 mL DMF were added EDCI.HCl (0.76 g, 4.0 mmol), HOBt (0.54 
g, 4.0 mmol) and DIPEA (2.0 ml, 12 mmol) and the resulting mixture was stirred overnight. It 
was then diluted with EtOAc (120 mL), washed with conc. aq. NaHCO3 (30 mL), 10% NaCl (30 
mL), brine (30 mL), and concentrated. The resulting methyl ester intermediate was taken up in 
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4:1 THF:MeOH (30 mL) and aq. NaOH (25%, 5 mL) was added. After the reaction mixture was 
stirred overnight, it was quenched with aq. HCl (2.4 M, 50 mL) and extracted with EtOAc (2 x 
100 mL). Combined organic extracts were washed with brine (30 mL) and concentrated 
affording 9 (1.22 g, 100%). Data for 9: MS calc (M-H)
-
 301.1552, found 301.15; NMR (CDCl3) 
 8.37 (s, 0.9H), 7.57 (d, 1H, J = 7.8 Hz), 7.33 (d, 1H, J = 7.3 Hz), 7.16 (m, 1H), 7.09 (m, 1H), 
6.97 (s (br), 1H), 5.59 (s, 0.9H), 3.11 (br, 4H), 2.57 (br, 2H), 2.26 (t, 2H, J = 7.4 Hz), 1.53 (br, 
2H), 1.31 (br, 2H), 1.14 (br, 2H). 
10.  To a solution of carboxylic acid 9 (75.4 mg, 0.249 mmol) and amine 3a (149 mg, 0.276 
mmol) in 2.0 mL dry DMF were added EDCI.HCl (56.5 mg, 0.29 mmol), HOAt (41.8 mg, 0.31 
mmol) and DIPEA (0.13 ml, 0.75 mmol) and the resulting mixture was stirred for 48 h. It was 
then diluted with EtOAc (30 mL), washed with conc. aq. NaHCO3 (15 mL), 10% NaCl (15 mL), 
brine (15 mL), and concentrated. Purification by silica gel chromatography (4:1 EtOAc:hexanes 
 EtOAc) afforded tBu ester-protected intermediate (205 mg, 100%). Rf = 0.30 (4:1 
EtOAc:hexanes). 
This intermediate (153 mg) was taken up in dry HCl in dioxane (4 M, 2.5 mL), stirred for 2 h, 
and concentrated. Purification by silica gel chromatography (10:1 DCM:MeOH) afforded 10 





H NMR (acetone)  8.34 (s, 0.4H), 8.32 (s, 0.5H), 8.15 (s, 0.7H), 7.67 (m,2H), 7.56 (d, 
1H, J = 7.8 Hz), 7.47 (s (br), 1H), 7.41 (m, 2H), 7.35 (d, 2H, J = 8.2 Hz), 7.27 (br, 2H), 7.18 (t, 
1H, J =5.5 Hz), 7.12 – 6.96 (m, 7H), 4.99 (m, 1H), 4.29 (t, 2H, J = 6.2 Hz), 3.52-3.35 (m, 2H), 
3.24 (t, 2H, J = 6.4 Hz), 3.18 (q, 2H, J = 6.4 Hz), 3.07 (t, 2H, J = 7.6 Hz),  2.56 (t, 2H, J = 7.6 
Hz), 2.14 (t, 2H, J = 7.6 Hz), 1.53 (t, 2H, J = 7.6 Hz), 1.43 (t, 2H, J = 7.6 Hz), 1.25 (m, 2H). 
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11.  To a solution of carboxylic acid 9 (60.0 mg, 0.198 mmol) and amine 4a (102 mg, 0.2 mmol) 
in 2.0 mL dry DMF were added EDCI.HCl (58.4 mg, 0.305 mmol), HOAt (33.4 mg, 0.245 
mmol) and DIPEA (0.10 ml, 0.57 mmol) and the resulting mixture was stirred overnight. It was 
then diluted with EtOAc (30 mL), washed with conc. aq. NaHCO3 (15 mL), 10% NaCl (15 mL), 
brine (15 mL), and concentrated. Purification by silica gel chromatography (19:1 DCM:MeOH) 
afforded tBu ester-protected intermediate (141 mg, 89%). Rf = 0.24 (10:1 DCM:MeOH). 
This intermediate (78.5 mg) was taken up in dry HCl in dioxane (4 M, 1.5 mL), stirred for 2 h, 
and concentrated. Purification by silica gel chromatography (9:1 DCM:MeOH) afforded 11 (45.7 





NMR (acetone)  10.01 (s, br, 0.3H), 9.87 (s, br, 0.6H), 8.51 (s, 0.7H), 8.32 (d, 1H, J=8.0 Hz), 
7.67 (d, 1H, J=7.7 Hz), 7.55 (m, 2H), 7.46 (m, 3H), 7.43-7.31 (m, 6H), 7.27 (s, 1H), 7.10-6.95 
(m, 5H), 5.02 (m, 1H), 3.50 (dd, 2H, J=14.4, 4.8 Hz), 3.37 (m, 2H), (m, 2H), 3.04 (t, 2H, J=7.2 
Hz), 2.52 (t, 2H, J=7.8 Hz), 2.37 (t, 2H, J=7.4 Hz), 2.22 (q, 2H, J=5.8 Hz), 1.62 (t, 2H, J=7.4 
Hz), 1.44 (t, 2H, J=7.4 Hz), 1.29 (m, 2H). 
2.2 Assays 
2.2.1 Fluorescence binding assay Inhibition constants Ki for binding in the hydrophobic 





(env2.0)3 was used to mimic the hydrophobic pocket in the gp41 NHR coiled coil.  Env2.0 
has the sequence bpy-GQAVEAQQHLLQLTVWGIKQLQARILAVEKK-amide, where bpy is 
2,2-bipyridine-5-carboxylate, a bidentate ferrous iron chelator that assures the trimeric structure 
of the NHR upon metal binding.  Underlined residues occur in WT HXB2 gp41. C-peptide 
C18e2.0-FL (Ac-MTWBEWDREIBNYTSLIC, B = -aminoisobutyric acid, WT residues 
underlined) labeled with fluorescein at the cysteine residue, was used to probe inhibitor binding.  
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Quenching of C18e2.0-FL occurred upon addition of Fe
II
(env2.0)3, with a KD = 0.8 µM and a 
minimal fractional fluorescence for the complex = 0.072. KI was determined by measuring the 
dose dependent fluorescence recovery in the presence of a competitive inhibitor.  7.2 µM 
Fe(env2.0)3 (measured as concentration of HP binding sites, with three equivalent sites per 
trimer) and 30 nM C18e2.0FL were used in the competitive inhibition experiments, with serial 
dilution of the inhibitors in the range 0.39 – 400 µM, in Tris-acetate buffer at pH 7.0 and 4% 
DMSO.
25
  Concentration of dimeric inhibitors was calculated as one molecule per dimeric unit.  
12 points per binding curve were measured in triplicate for each compound.  Fractional 
fluorescence data were fit to equations (3) and (4) for 1:1 ligand : HP binding (Section 3.3).  For 





D   RL;  KD 
[R][L]
[RL]
;  Lt  [L] [RL]
R  I 
K
I1   RI; KI1 
[R][I]
[RI]
;  R t  [R] [RL] [RI] 2[R2I]
RIR 
K
I2   R2I;  KI2 
[RI][R]
[R2I]
;  It  [I] [RI] [R2I]
                          (1)
 
 
where Lt, Rt and It are the concentrations of probe, HP binding sites in receptor Fe(env2.0)3,  and 
inhibitor, respectively, KI1 and KI2 are the inhibition constants for the first and second binding 
interactions.  The observed fractional fluorescence was calculated from equation (3).   




SSQ  {max((| Fobs,i
i1
12
 Fcalc,i | i ),0)}
2
     (2) 
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where Fobs,i and Fcalc,i are the fractional fluorescence and si is the standard deviation of each data 
point.  
2.2.2 Surface Plasmon Resonance Experiments Experiments were carried out on a Biacore 
T100 instrument.  A CM5 sensor chip surface was activated by injecting 360 µl EDC/NHS 
(freshly prepared by mixing 5 mM EDC and 5 mM NHS (1:1 v/v) in biacore HBS-EP buffer), 
followed by introduction of 150 µl PDEA (80 mM in 0.1 M sodium borate buffer, pH 8.5) at a 
flow rate of 20 µl/min. The bioreceptor Fe
II
(envC)3 (envC = bpy-
GQAVEAQQHLLQLTVWGIKQLQARI(d)C-amide, WT HXB2-Env residues underlined)) was 
then bound to the sensor chip surface by injecting 150 µl (5 µM Fe
II
(envC)3 in 25 mM Tris-
acetate buffer, pH 7.0) for 2 – 9 minutes at 10 µl/min.  Unreacted disulfide surface was 
deactivated with 50 µl L-cysteine (50 mM in 0.1 M sodium acetate buffer, 1 M NaCl, pH 4.5) 
followed by a wash with 200 µl of freshly prepared 1 mM ferrous ammonium sulfate at 20 
µl/min, to ensure that any ferrous ion leached at low pH was restored.  Any non-specifically 
bound material was removed with 50 µl of 500 mM NaCl at 50 µl/min.  An equivalent reference 
surface was generated using the same procedure as above excluding the Fe
II
(envC)3 coupling 
step.  Analytes were detected at serially increasing concentrations from 0.098 to 50 µM in Hepes 
buffered saline (20 mM Hepes, 150 mM NaCl) at pH 7.0 containing 1% DMSO, using a 60 s 
association time and 300 s dissociation time.  DMSO bracketing was used to correct the 
refractive index.  Analysis of sensorgram data was carried out with Biacore Biaevaluation 
software. 
2.2.3 Cell-cell Fusion Assay Cell-cell fusion was measured using cell lines obtained through the 
NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. Target 
cells were TZM-bl cells (#8129, contributed by J.C. Kappes, X. Wu and Tranzyme Inc.) 
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expressing CD4, CCR5 and CXCR4,
26
 and containing an integrated reporter gene for firefly 
luciferase under control of HIV-1 LTR.
27
  Effector cells were HL2/3 (#1294, contributed by B.K. 
Felber and G.N. Pavlakis) which produce HXB2 Env, Tat and Rev.
28
 Serially diluted inhibitors 
were added to 96 well plates containing 25,000 TZM-bl cells per well cultured overnight.  
50,000 HL2/3 cells were added per well, and fusion allowed to proceed for 6 hours in reduced 
serum medium (Gibco) with a final concentration of 1% DMSO. Luciferase expression was 
measured using Luciferase Assay Reagent (Promega) according to the manufacturer’s 
instructions. Controls containing 1% DMSO with and without HL2/3 cells were measured for 
each compound, and experiments were performed in triplicate. 
2.2. 4 Viral Replication and Attachment Assays Inhibition of HIV-1 replication was 
determined in CCR5- and CXCR4-tropic MAGI antiviral assays and inhibition of HIV-1 
attachment/entry was determined in CCR5-tropic MAGI attachment assays as previously 
described.
29, 30
  HIV-1 isolates and cells were obtained from the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH, as follows:  HIV-1 Ba-L from 
Suzanne Gartner, Mikulas Popovic, and Robert Gallo.
30, 31
 HIV-1 IIIB from Robert C. Gallo.
30, 32
  
MAGI-CCR5 cells from Dr. Julie Overbaugh.
33, 34
 For MAGI antiviral assays, MAGI-CCR5 
cells were grown overnight in 96 well plates in DMEM supplemented with 10% FBS, using 
10,000 cells per well.  The following day the medium was removed and compounds diluted in 
medium were added (6 dilutions in triplicate at each dilution), followed by the addition of either 
HIV-1 Ba-L (CCR5-tropic assay) or HIV-1 IIIB (CXCR4-tropic assay) at approximately ten 
50% tissue culture infective doses per well (~10 TCID50/well).  Assay plates were incubated for 
48 hours, after which medium was removed and HIV-1 Tat-induced β-Gal enzyme expression 
was determined by chemiluminescence using Tropix Gal-Screen (Applied Biosystems) 
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according to the manufacturer’s instructions.  MAGI attachment assays were performed 
similarly, but with a washout of unbound virus and compounds three (3) hours post-infection.  
Assays were conducted at a serum concentration of 2%. 
2.2.5 Cytotoxicity Assay The cytotoxic effect of the compounds was determined using the 
identical cell culture procedure to that described above for viral replication or cell-cell fusion, 
but measuring cell viability, using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS, CellTiter 96 reagent; Promega; used for MAGI assays) or 
using a resazurin cell viability reagent (Alamar Blue or Presto Blue, Life Technologies; used for 
cell-cell fusion assays) following the manufacturers’ protocols. 
2.3 Computational docking 
Ligand charges and low energy conformations were obtained using OpenEye software
35, 36
 
(fixpka, molcharge, omega2-2.5.1.4 and szybki, OpenEye Scientific Software, Santa Fe, NM. 
http://www.eyesopen.com).  Compounds were docked into pdb structure 3P7K using Autodock 
Vina.  A model of bivalent binding of the dimer 7 (Figure 3) was obtained using low energy 
conformers of two partial structures, split at the edge of the PEG3 linker.  Structures were docked 
and linker dihedrals were manually adjusted to reconnect the two parts.  The local geometry was 
then optimized and clashes removed using the default minimization protocol in Chimera (UCSF) 
(Potential energy of complex -12.4 x 10
3
, RMSD 0.0244 Å over 2460 atoms). 
3. Results 
3.1 Synthesis and Description of Compounds   Six compounds were prepared as shown in Figure 
2 and Schemes 1 - 3. There were two series, based on the two-subunit peptidomimetic 
compounds 3 (H2N-[Trp]-Trp-OH) and 4 (H2N-[Phe4Cl]-Trp-OH), designated “monomers”.  
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Dimers 7 and 8 had two peptidomimetic monomers connected by a 22.5Å succinate-PEG3-
succinate spacer (PEG3 = triethylene glycol), calculated to be sufficiently long to permit 
simultaneous binding into two hydrophobic pockets of the HR1 trimer.  A model of 7 produced 
 
Figure 2.  Structures of peptidomimetic inhibitors used in this study 




by docking into the HR1 trimer and energy 
minimization (see Materials and Methods) is shown 
in Figure 3.  The two monomers reach into two HP’s 
of the trimer with the PEG linker units in mostly all 
trans conformation.  Extended monomers 10 and 11 
were substituted at the aniline with a hydrophobic 
alkyl tail terminated by a Trp, with the goal of 
increasing interactions within the HR1 groove beyond 
the HP.  LC-MS and NMR figures of the final 
compounds are shown in Supplementary Data Figures 
S1 and S2. 
3.2 Anti-fusion activity improved with compound 
elaboration Activity of the two series of 
compounds was investigated in cell – cell fusion 
(CCF) assays using effector cells expressing CXCR4-tropic HXB2-Env, and in virus – cell 
fusion (VCF) assays using laboratory adapted strains Ba-L (CCR5-tropic) and IIIB (CXCR4-




Figure 3.  Model showing the ability of dimer 7 
to reach around the HR1 coiled coil with the 
terminal –NH-[Trp]-Trp-OH units interacting 
in two hydrophobic pockets.  The surface 
representation of the HR1 (pdb 3P7K) has 
been made partly transparent to reveal the 




tropic).  The results are shown in Figure 4 and Table 1.  CCF was inhibited more readily than 
VCF, and augmenting the basic monomer significantly improved anti-fusion activity.  None of 
the compounds exhibited any toxicity at the concentrations tested.   
Scheme 3.  Addition of a hydrophobic tail to monomers 3 and 4, forming 10 and 11
 
 
Figure 4.  Dose-response curves for each compound demonstrating percent inhibition of cell-cell 
fusion (A, B) and Ba-L viral infectivity (C, D) measured as relative luminescence units (RLU) using a 
luciferase reporter.  A, C.  Compounds 3 (blue), 7 (black), 10 (red); B, D. Compounds 4 (blue), 8 
(black) and 11 (red).  Cell viability is shown in corresponding open circles.  Error bars are standard 




Table 1.  Activity data against HIV-Env mediated fusion* 
 cell-cell fusion virus- cell fusion CC50 
 HXB2 Ba-L IIIB  
Compounds IC50 IC90 IC50 IC90 IC50 IC90  
3 22 80 > 50 > 50 > 50 > 50 > 50 
10 1.3 15.1 13.7 31.1 17.3 30.5 > 100 
7 0.6 6.3 3.6 >100 3.8 70.0 > 100 
4 24 49 > 50 > 50 > 50 > 50 > 50 
11 2.2 5.6 13.0 26.5 14.3 27.1 > 100 
8 0.4 4.4 4.7 18.3 5.1 20.8 > 100 
*3-6 repeats of each measurement, error is 10-20%, in µM 
Monomers H2N-[Trp]-Trp-OH and H2N-[Phe4Cl]-Trp-OH were weak CCF inhibitors (22 – 24 
µM) and were ineffective against VCF.  Activity improved to 1 -2 µM against CCF and 13 – 17 
µM against VCF with addition of the hydrophobic tail in compounds 10 and 11.  Many studies 
indicate that increased hydrophobic character is consistent with increased fusion inhibitory 
activity,
37






) of this 
peptidomimetic library (Figure 2).   The added hydrophobic tail with the terminal Trp may 
interact in the HR1 groove of the hydrophobic gp41 protein, or may associate with the lipid 
bilayer, orienting and concentrating the ligand in the biological milieu of the fusion reaction.   
Dimerization of the inhibitors with a 22Å PEG linker connecting two monomers resulted in the 
best performing member of each series, with compounds 7 and 8 having IC50’s < 1 µM against 
CCF and 3-5 µM against VCF.  In this case, it is not expected that the PEG linker would interact 
extensively with the membrane,
20
 suggesting that additional HR1 interactions could form the 
basis of the improved activity.  We noted that the antiviral activity of 7 reached a plateau at 
~20% residual fusion activity of Ba-L virus and ~6% residual fusion activity of IIIB virus.  The 
faster kinetics of Ba-L fusion may limit the potency of the largest molecular weight inhibitor 7. 
  
21 
3.3 Solution binding studies confirmed hydrophobic pocket binding  Next we wished to 
ascertain whether the 50-fold increase in potency was a cooperative effect of dimers binding into 
two HP’s of one HR1 trimer, as designed.  We therefore examined whether binding and kinetic 
data could discriminate between a monovalent and bivalent binding mechanism.  Affinity of the 
compounds for the gp41 HP was determined by fluorescence using a competitive inhibition 
assay that has been previously described.
14, 25
 Briefly, the hydrophobic pocket (receptor R) is 
formed by metal ion assisted association between three HR1 peptides env2.0 spanning the pocket 
sequence (HXB2 residues 560 – 584) that are covalently linked to N-terminal 2,2’-bipyridine 
(bpy).  Ferrous ion binding in 1/3 stoichiometry to peptide results in spontaneous formation of an 
HR1 trimeric coiled coil as a magenta-colored complex Fe(env2.0)3.  The fluorescence of HR2 
probe peptide (HXB2 residues 626-642) labeled with fluorescein at the C-terminus (L = C18-
e2.0FL) is quenched upon binding to Fe(env2.0)3, forming the basis of the fluorescence assay.  
Compounds binding to the HP displace the probe peptide with a concomitant increase in 
fluorescence.  Inhibition constants (KI) are determined by dose response measurements.  Data 
were fit to the equation 
 

Fobs  FRL  (FL FRL)
KD
KD  [R]
     (3)   
where KD is the dissociation constant of the Fe(env2.0)3-C18-e2.0FL complex, and FL and FRL 
are the fluorescence of free and bound C18-e2.0FL. Known parameters are KD = 0.8 µM and 
fractional FRL = 0.072.
14
   
For 1:1 binding of ligand with HP’s on the trimer Fe(env2.0)3, the concentration of free HP, [R], 
was calculated analytically according to the equation 
  

[R] {Rt  It KI  (Rt  It KI )4RtKI}/2   (4)  
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Rt, It and Lt are the total concentrations of added receptor binding sites, inhibitor and probe 
peptide respectively, and KI is the inhibition constant.  Equation (4) is an analytical 
approximation valid when Rt >> Lt which is fulfilled by the experimental conditions.  Equation 
(3) was also solved numerically for both 1:1 and 1:2 binding models, requiring no 
approximations (Materials and Methods).  The analytical approximation of 1:2 binding of ligand 
to two HP’s required solution of a cubic equation and was not used. 
3.3.1 Avidity for the HP did not predict the order of observed biological activity      In 
previous studies, we have shown a correlation between low µM binding to Fe(env2.0)3 and 
inhibition of HIV-fusion.
5, 6, 23
 Competitive inhibition dose response curves for 3, 4, 7, 8, 10 and 
 
Figure 5.  Fluorescence competitive inhibition dose response curves performed with 7.2 µM binding 
sites.  A. 3 (blue), 7 (black), 10 (red) and B. 4 (blue), 8 (black), 11 (red).  C and D show data fitting for 
dimers 7 and 8 to a 1:1 binding model (dashed line) and 1:2 binding model (bold solid line) assuming 
7.2µM binding sites.  The narrow solid lines show an alternative fit to a 1:1 binding model with 40% 
reduced receptor concentration. RFU = relative fluorescence units, as a fraction of the fluorescence of 
probe plus compound in the absence of receptor (FL). 
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11, conducted using 7.2 µM Rt and 30 nM Lt, are shown in Figure 5A and 5B.  Here too, we 
observed that low µM inhibition in the binding assay was commensurate with activity against 
HIV-Env mediated fusion; however it was not completely correlated. A higher concentration was 
required for 50% activity of dimer compared to the corresponding extended monomer in the 
fluorescence assay, while dimers were clearly more potent in biological assays.  Additionally, the 
slope of the binding curves was lower for the bivalent inhibitors.  Parameters FL, Rt and KI were 
determined from dose response curves by fitting to equations 1 and 2, and / or by numerical 
simulation.  Results are given in Table 2. 
Table 2. Results of fluorescence equilibrium binding assay for the 













3 (monomer) 1:1 1.08 7.2 KI = 7.2 ± 1.1 2.13 
10 (extended monomer) 1:1 0.85 6.2 KI = 1.2 ± 0.2 2.07 
7 (dimer) 1:1 0.79 7.2 KI = 1.0 ± 0.3 
§
 10.11 
 1:1 0.80 4.3 KI = 2.3 ± 0.3 0.014 
 1:2 0.95 7.2 KI1 = 20, KI2 = 0.2 0.928 
4 (monomer) 1:1 1.00 7.2 KI = 15 ±
 
2.6 0.258 
11 (extended monomer) 1:1 0.85 5.5 KI = 3.4 ± 0.18 0.066 
8 (dimer) 1:1 0.99 7.2 KI = 5.3 ± 1.5 
§
 18.7 
 1:1 0.90 4.5 KI = 8.5 ±1.3 0.596 
 1:2 1.05 7.2 KI1 = 21, KI2 = 1.3 0.168 
† Data were fit to equations (3) and (4) or (1), and the sum of squares SSQ was 
calculated using equation (2), see text. 
‡
 The binding model is defined as the ratio 
of ligand : HP. 
§
Poor fit.  The total HP concentration in the assay, Rt, was 7.2 µM.  
Maximum fractional fluorescence FL < 1 could be due to light scattering 
 
3.3.2 Monomers and extended monomers could be fit to a 1:1 binding model   Fluorescence 
data for monomers 3 and 4 were simulated by a 1 ligand  : 1 HP binding model, with the 
expected concentration of HP, Rt = 7.2 µM.  Fits to the data for extended monomers 10 and 11 
yielded Rt values that were 14-20% lower than those of the corresponding monomer, which we 
interpreted as an outcome of the low solubility of these hydrophobic inhibitors, causing 
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aggregation of the receptor – compound complex.   Consequently, the aggregates caused light 
scattering in the fluorescence assay, leading to values for FL < 1 (Table 2). [Trp]-Trp containing 
peptidomimetic compounds 3 and 10 were measurably more potent than [Phe4Cl]-Trp 
compounds 4 and 11, consistent with their higher hydrophobic character.  Observed inhibition 
constants were 7 µM for 3, 15 µM for 4.  Adding the hydrophobic tail improved HP binding 
affinity by a factor of 5 to 6, to 1.2 for 10 and 3.1 for 11, mirroring the results obtained in fusion 
inhibition studies and further consolidating the role that hydrophobic character and HP binding 
play in compound activity. 
3.3.3 The data are compatible with a bivalent interaction of dimers with Fe(env2.0)3 Using 
the experimental value of Rt = 7.2 µM, fluorescence data for the bivalent inhibitors 7 and 8 could 
not be fit to a 1:1 binding model.  Instead, data fitting supported a model in which simultaneous 
binding of one bivalent ligand into two hydrophobic pockets occurred (Table 2, Figure 5C, D, 
Figure 6).  Since there are three HP’s per trimer, the simplest model for full occupancy of the 
HP’s would include a bidentate bound dimer and a monodentate bound dimer (Figure 6).  This 
leaves only 67% of receptor binding sites available for the total number of dimer molecules.  An 
excellent fit to the data was in fact achieved using a 1:1 binding model with ~40% reduction in 
Rt.  These fits yielded KI’s of 2.3 µM and 8.5 µM for 7 and 8, respectively, 2 – 3 fold improved 
over the respective monomers. The observed KI’s are assumed to be an average over 
monodentate and bidentate binding.  Best fit Rt values at ~60% implicate some aggregation as 
part of this model fitting, supported by the observation of FL values < 1. 
The data could also be fit with the full complement of Rt= = 7.2 µM using a model of 1:2 
binding of one bivalent ligand : 2 HP’s.  Notably the binding constant for the first interaction, KI  
= 20 to 21 µM, was higher than the KI for the monomers 3 or 4, and likely reflects an entropic 
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penalty due to the flexible PEG linker, while KI2 for the second interaction at the other end of the 
PEG linker was more than an order of magnitude lower than for the monomers, implying a 
cooperative binding effect or a local concentrating effect due to the first interaction. There was 
no evidence of aggregation from the FL values. The mathematical modeling does not specify 
whether the HP’s are on the same or different trimers, since they are each considered 
independent and identical.  It is unlikely that a ligand with the limited potency of 7 or 8 could 
bridge two trimers in solution.  Since the data fitting required every available HP, it is likely that 
a second bivalent inhibitor in the third site of each trimer engages in an equilibrium exchange for 
bidentate binding with the first bivalent inhibitor, as illustrated in Figure 6.   Data resolution does 
not permit us to distinguish this dynamic model from the static scenario described above. 
A third option for data fitting involves monodentate binding for all of the dimers, with a 
significant degree of receptor aggregation occurring during the assay.  We cannot formally rule 
out this possibility, given that the inhibitors are quite hydrophobic.  We therefore turned to 
surface binding studies to evaluate inhibitor interactions.   
3.4 Surface binding studies yielded kinetics of binding    Hydrophobic pocket binding was 
evaluated using surface plasmon resonance (SPR) to measure association and dissociation 
kinetics.  Analysis of the fluorescence data and previous literature observations
12
 suggested that 
bivalent binding should display an altered kinetic profile compared to 1:1 binding, permitting us 
 
Figure 6.  A model of bidentate binding of dimers to the HR1 trimer.  The HP’s, shown in 
orange, are arranged on a three-fold axis of symmetry. Each green diamond shape 
represents an aromatic side chain of the 2-subunit peptidomimetic monomer.  Two 
equivalent dimers are depicted in green and light green. 
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to verify our interpretation of the solution equilibrium binding studies.  Furthermore, we were 
curious to know whether kinetics, especially off-rate could be correlated more effectively to 
observed biological potency than KI, given that the target is a transient intermediate structure.  
Previous studies have shown that on-rate can limit the effectiveness of a large protein inhibitor,
38
 
and high potency is accompanied by a slow off-rate.
21, 39
 
SPR experiments were conducted on a Biacore CM5 chip using a modified version of the 
receptor peptide Fe(envC)3.  The peptide envC is terminated by a D-cysteine residue, which 
orients the thiol group along the axis of the peptide and permits vertical anchoring of the receptor 
to the surface groups.  We have previously used this receptor in electrochemical and SPR 
binding studies of peptide and small molecule – gp41 HP interactions.
40
 The design creates a 
homogeneous ligand surface with open binding sites on the three faces of the three-fold 
symmetrical receptor, such that dimers could simultaneously bind into two pockets, if that is 
indeed their mechanism.  
We achieved immobilization responses in the range 2460 – 5670 units, corresponding to 
approximately one Fe(envC)3 molecule per 32.6 – 8.3 nm
2
, respectively, or effective 
concentrations between 2.6 – 6 mM.
41, 42
 A reference channel was prepared without receptor, and 
signals from this channel were subtracted out to yield SPR sensorgrams that reflected 
interactions with Fe(envC)3.  Specificity of analyte binding was confirmed by observing both 
analyte and Fe(envC)3 concentration dependent responses (Supplementary Data, Figure S3).  
Typically, below ~10 µM, analyte responses were well below 100 RU, suitable for kinetic 
analysis.  At higher concentrations, most compounds gave disproportionately high analyte 
responses, likely due to non-specific binding or aggregation.  These sensorgrams were not 
included in the analysis.  
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 We measured the association rate (ka), dissociation rate (kd) and rate constant (KD = kd/ka) 
for each compound at various concentrations, by analyzing sensorgrams using Langmuir 1:1 
binding and 1:2 binding kinetic analysis.  The maximum analyte response, RUmax, occurring at 
saturating concentrations of analyte, was not obtained experimentally due to non-specific 
aggregation, and was determined from a good fit to SPR data for compound 7.  Remaining 
sensorgrams were fit by fixing RUmax proportionately according to the molecular weight of the 
analyte.  Uncertainty in RUmax led to ~30% uncertainty in ka, but still allowed us to compare 
kinetics within the compound set.  Off-rate kd was less dependent on RUmax.  The results are 
reported in Table 3, shown for the [Phe4Cl]-Trp series in Figures 7 and for the [Trp]-Trp series 
in Supplementary Data Figure S4.  The data clearly reveal significantly slower kinetics for 
bivalent compounds 7 and 8 compared to monovalent compounds 3 and 4, with intermediate 
rates observed for the extended monomers 10 and 11.  Monomers 3 and 4 had fast on- and off-






 and kd ~ 0.8 s
-1
.  Both on-rate and off-rate for dimers 




, and kd ~ 0.05 s
-1
.  The slow on-rate is 
likely due to the increased size and flexibility of the dimers, while the slow off-rate is consistent 
with dual binding interactions with Fe(envC)3 where there is a higher probability of rebinding 
before the partner can dissociate.  The extended monomers 10 and 11 have a large hydrophobic 





) kd / (s
-1





3 (monomer) 5.10e4 0.834 1.6e-5 59 4.54 
10 (ext. monomer) 1.10e4 0.093 1.4e-5 95 5.58 
7  (dimer) 0.37e4 0.060 1.6e-5 160 2.62 
4 (monomer) 6.70e4 0.820 1.2e-5 56 5.45 
11 (ext. monomer) 1.37e4 0.186 1.4e-5 93 2.90 
8 (dimer) 0.18e4 0.037 2.1e-5 157 1.68 
* RUmax was fixed during global curve fitting of sensorgrams at 3, 4 or 5 
concentrations for monomers, extended monomers or dimers, respectively 
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binding capacity and a flexible hydrophobic tail, which translated into intermediate values for ka 
and kd compared to the monomers and dimers, as well as lower KI’s observed by fluorescence. 
Changes of the same order of magnitude in both ka and kd resulted in little discrimination in KD  
over the dataset.  Values for KD obtained by the SPR experiment are of limited accuracy due to 
low precision in ka and the inability to reach saturating concentrations of analyte. 
3.4.1 A bivalent model gave an improved fit to the SPR data for the dimers We observed 
improved fits to the data for the dimers using a bivalent analyte binding model provided by the 
Biacore software, (Figure 7D and S4D).   The results of the data fitting are shown in Table 4.   
 
Figure 7.  SPR sensorgrams obtained with immobilized Fe(envC)3. The chip was exposed to 
compounds for 60s, followed by 300s dissociation time.  Data were collected from -50 to 360 s 
and are shown expanded in the figure between -10 to 150 s.  A. Compound 4, at concentrations 
6.25, 3.13, 1.56 µM; B.  Compound 11, at concentrations 6.25, 3.13, 1.56, 0.78 µM; C, D. 
Compound 8, at concentrations 6.25, 3.13, 1.56, 0.78, 0.39 µM.  Data were fit to a 1:1 binding 
kinetic model (A – C) or assuming bivalent analyte (D).  Residuals between observed and 
calculated data are shown below each sensorgram. 
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The observation that kd1 > kd2 suggested that bivalent interactions make an important 
contribution to slowing the off-rate, and therefore to potency against fusion. 
 
3.4.2 Kinetic rates correlated with inhibitor potency The relatively small change in KI 
between monomers and dimers can be explained by the high entropic penalty due to constraining 
the flexible structures.  7 and 8 have 35 and 33 rotatable bonds, respectively, 19 of which involve 
the flexible succinimidyl-PEG3 linker.
43
 For the extended monomers, observed KI were lower 
and ka’s higher than for the dimers, confirming that the additional hydrophobic contribution to 
enthalpy more than offset the entropic penalty due the 18 – 19 added rotatable bonds.  The 
biophysical properties of the dimers provided evidence that slow kinetics was a more important 
quality for inhibiting fusion than the KI, since 7 and 8 were more than an order of magnitude 
more potent as fusion inhibitors than 3 and 4, and several times more potent than 10 and 11.  
Table 4.  Biacore fitting of dimer data to a bivalent binding model 
 ka1 (M-1s-1) kd1 (s
-1













7 2691 0.0869 3.2e-5 4.54e-5 0.0145 160 2.95 
8 1489 0.0638 4.3e-5 2.27e-5 0.0033 157 0.44 
 
Figure 8. Correlations between kinetic data and fusion inhibition. A. Dissociation rate kd and B. 




They also explain the lower correlation observed between fusion inhibition and KI compared to 
kd, as shown in Figure 8.  We note that ka also correlated with inhibitor potency (not shown).  
 
4. Discussion 
In this study, we evaluated the binding affinity, kinetics and biological activity of 
peptidomimetic inhibitors that were modified to extend interactions with gp41 beyond the HP.  
The core units were arylalkoxy-amino acid helical mimetics supporting side chains at the 
equivalent of i and i+3 positions of a helix.  These were 3 (H2N-[Trp]-Trp-OH) and 4 (H2N- 
[Phe4Cl]-Trp-OH).  Previous studies have identified these molecules as moderate hydrophobic 
pocket binders and fusion inhibitors.
23, 24
 Onto these monomeric units, we grafted a largely 
flexible hydrophobic tail that could extend the interaction of the inhibitor into the long 
hydrophobic groove (compounds 10 and 11).  Alternative structures were created with a flexible 
PEG linker supporting two monomeric units at either end, which could purportedly interact 
simultaneously with hydrophobic pockets on two faces of the coiled coil.  These were 
compounds 7 (dimer of –HN-[Trp]-Trp-OH) and 8 (dimer of –HN-[Phe4Cl]-Trp-OH).   Fusion 
inhibition studies revealed that monomers were poor to moderate inhibitors, monomers extended 
with a hydrophobic tail were more potent, and the bivalent compounds with a monomer unit at 
each end of the long 22.5 Å spacer were the most potent fusion inhibitors.  KI’s were obtained by 
equilibrium binding studies using fluorescence, and kinetic data were obtained by SPR.  Data for 
3, 4, 10, and 11 conformed to a 1:1 binding model, while data for the dimers 7 and 8 were 
commensurate with bidentate binding.  Optimal fits of the dimer data were obtained with a 1:2 
ligand : HP binding model (Figures 5 and 7), yielding two inhibition constants KI1 and KI2 for the 
first and second binding event, or by proportionate reduction in binding site concentration in a 
1:1 model in which a maximum of two dimer molecules associate with each HR1 trimer, 
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yielding a single average <KI>.  Significantly reduced dissociation constants were obtained 
compared to monomers, presumably due to rebinding events.  The data could be interpreted as 
monodentate binding of dimer molecules, although this required the assumptions that 40% of the 
receptor aggregated during the binding assay, and that slow dissociation was simply a 
consequence of the large number of degrees of freedom in the dimers.
44
  
The variation of KI’s across the data set was lower than the differences in their biological 
activity. The 6-fold reduction in KI caused by adding a flexible hydrophobic tail in 10 and 11 
improved biological activity by a factor of 10 - 15, while dimers 7 and 8 were 40 – 60 fold more 
active than the monomers against fusion, despite only 2 -3 fold changes to <KI>.  Examination of 
the kinetic data revealed that dissociation rate kd was better correlated to biological activity than 
KI.  Dimers dissociated ~ 20 times more slowly than monomers.  
ka also decreased with increasing size of the inhibitors, a consequence of both size and 
the loss of conformational entropy upon binding.
44
 Consequently, the range of KI = kd/ka 
remained small.  This is the enthalpy – entropy compensation effect, whereby structural mobility 
provided for enthalpic contributions through enhanced conformational search space and number 
of interactions, but simultaneously resulted in a large entropic penalty from inhibitor 
rigidification upon binding.
43
 In this context, even the monomeric units with 8 - 9 rotatable 
bonds have poor avidity.  The number of rotatable bonds increased to 18-19 for 11 and 10, and 
33 – 35 for 8 and 7, clearly a limiting factor in the potency of the resulting molecules.  It also 
affected the degree of cooperativity of bidentate binding in the dimers.  Slight cooperativity was 
apparent from the lower average inhibition constant of dimers compared to monomers and the 
observation of KI2 << KI1, and kd2 < kd1 in bivalent model fitting, but it was significantly 
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dampened by the length and flexibility of the spacer between the two monomers, resulting in a 
large KI1 and low ka1.  
By contrast, there was significant cooperativity observed in fusion inhibitory activity of 
the dimers, suggesting that the biological milieu is not emulated by the biophysical setup.  A 
factor of 2 – 3 in <KI> became a factor of 40 – 60 in IC50.  One possible explanation is that the 
transient nature of the biological target accentuates the role of inhibitor kinetics in potency.  
Previous studies have shown that potency of HP binding inhibitors is highly dependent on the 
rate of the fusion reaction.
21
 The low off-rate for the dimers could result in gp41 molecules 
trapped in the inhibitor-bound state or cause an off-pathway effect.
39
 Another possibility is that 
the local environment of gp41 near the membrane alters the behavior of the inhibitors due to 
association of hydrophobic moieties with lipids.  Addition of a lipid-binding moiety to a peptide 
is known to enhance peptide potency by orienting and concentrating the peptide at the site of 
action.
45-47
 Yet a third possible explanation is that the cooperativity does not arise from bidentate 
interactions with one HR1 trimer, but rather by the bridging of two trimers on the cell or virion 
surface. This was suggested to be the mechanism of 20 – 100 fold increased potency of bivalent 
sialosides against Influenza Virus mediated hemagglutination, where, similar to our 
observations, a minimal increase in binding affinity to an isolated trimer occurred for the 
dimers.
48
 This mechanism appears somewhat less likely due to the low receptor density on the 
surface of HIV, where there are estimated to be ~ 14 Env trimers per virion, compared to ordered 
arrays of 500 – 1000 HA trimers per Influenza virion.
48, 49
 However, if more than one HIV Env 
trimer congregates to form the fusion pore, it could provide a window of susceptibility for a 







In conclusion, we have observed ~ 50 fold improvement in fusion inhibitory activity 
upon dimerization of small peptidomimetic two-subunit compounds containing Trp and Phe4Cl 
residues.    Off-rate was found to be a more sensitive predictor of fusion inhibitory activity than 
KI.  Our data are consistent with bidentate binding of the dimer molecules to the gp41 trimer, 
with slow dissociation rates due to rebinding events, notwithstanding the low cooperativity of 
dimer binding.  The failure of solution binding to recapitulate the cooperative effect observed in 
fusion inhibition is likely due to linker flexibility and to the effect of kinetics on the inhibitory 
potency of the dimers.  By way of comparison, a range of 10 - 300 fold improvement in fusion 
inhibitory activity was found by dimerizing D-peptide inhibitors, a variation that was related to 
the viral strain-dependent rate of fusion.
20, 21
 Trimerization of D-peptides improved activity by a 
factor of 1000 or more.
20, 21
 The mechanism was assumed to be due to tridentate binding to one 
HR1 trimer, but no specific experiments confirmed this binding mechanism.  We have shown 
that multimerization is an applicable strategy for improving non-peptide fusion inhibitors.  Local 
modifications to the structures to improve their thermodynamic parameters, as well as globally 
increasing multivalency, could yield orders of magnitude increase in potency.  Importantly, these 
inhibitors utilize specific HP interactions rather than non-specific hydrophobic or electrostatic 
interactions
51
 which can yield low µM binding to gp41 HR1 but are difficult to optimize. In this 
regard, it is likely that non-specific hydrophobic interactions will limit our ability to optimize 
inhibitors such as 10 and 11.  Our results demonstrate proof of principle of a method to enhance 
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Figure 1.  Experimental and model structures of the gp41 HR1 – HR2 domain and interactions.  
A.  Homology modeling of HIV-1 HXB2 ectodomain from the structure of the corresponding 
SIV domain (pdb 2EZO).  The HR1 trimer is shown as a space filling model in tan, and loop and 
HR2 residues are shown as a ribbon representation in yellow;  B.  Expansion of the hydrophobic 
pocket region from A.  C.  Crystal structure (pdb 2R5D) of D-peptide PIE7 showing Trp and Leu 
residues filling the pocket; D, E. Modeled low energy structures of two subunit and three subunit 
peptidomimetics with Trp and Leu residues filling the pocket.  See Figure 2 for the structures of 
the peptidomimetic inhibitors. 
Figure 2.  Structures of peptidomimetic inhibitors used in this study.  
Figure 3.  Model showing the ability of dimer 7 to reach around the HR1 coiled coil with the 
terminal –NH-[Trp]-Trp-OH units interacting in two hydrophobic pockets.  The surface 
representation of the HR1 (pdb 3P7K) has been made partly transparent to reveal the docked 
aromatic rings of 7. 
Figure 4.  Dose-response curves for each compound demonstrating percent inhibition of cell-cell 
fusion (A, B) and Ba-L viral infectivity (C, D) measured as relative luminescence units (RLU) 
using a luciferase reporter.  A, C.  Compounds 3 (blue), 7 (black), 10 (red); B, D. Compounds 4 
(blue), 8 (black) and 11 (red).  Cell viability is shown in corresponding open circles.  Error bars 
are standard deviations of three measurements.  
Figure 5.  Fluorescence competitive inhibition dose response curves performed with 7.2 µM 
binding sites.  A. 3 (blue), 7 (black), 10 (red) and B. 4 (blue), 8 (black), 11 (red).  C and D show 
data fitting for dimers 7 and 8 to a 1:1 binding model (dashed line) and 1:2 binding model (bold 
solid line) assuming 7.2 µM binding sites.  The narrow solid lines show an alternative fit to a 1:1 
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binding model with 40% reduced receptor concentration. RFU = relative fluorescence units, as a 
fraction of the fluorescence of probe plus compound in the absence of receptor (FL). 
Figure 6.  A model of bidentate binding of dimers to the HR1 trimer.  The HP’s, shown in 
orange, are arranged on a three-fold axis of symmetry. Each green diamond shape represents an 
aromatic side chain of the 2-subunit peptidomimetic monomer.  Two equivalent dimers are 
depicted in green and light green. 
Figure 7.  SPR sensorgrams obtained with immobilized Fe(envC)3. The chip was exposed to 
compounds for 60s, followed by 300s dissociation time.  Data were collected from -50 to 360 s 
and are shown expanded in the figure between -10 to 150 s.  A. Compound 4, at concentrations 
6.25, 3.13, 1.56 µM; B.  Compound 11, at concentrations 6.25, 3.13, 1.56, 0.78 µM; C, D. 
Compound 8, at concentrations 6.25, 3.13, 1.56, 0.78, 0.39 µM.  Data were fit to a 1:1 binding 
kinetic model (A – C) or assuming bivalent analyte (D).  Residuals between observed and 
calculated data are shown below each sensorgram. 
Figure 8. Correlations between kinetic data and fusion inhibition. A. Dissociation rate kd and B. 
















 Bivalent gp41 inhibitors were 40 – 60 fold more potent than monomers. 
 Binding potency was not significantly improved by dimerization.  
 Potency was correlated to slower off-rates. 
 Data could be explained by a bidentate binding model for the dimers. 
 The kinetic dependence may be due to transience of the targeted intermediate. 
 
 
